Abstract

Simple SummaryLynch-like syndrome (LLS) is defined as colorectal cancer cases with microsatellite instability (MSI) and loss of expression of MLH1, MSH2, MSH6, or PMS2 by immunohistochemistry (IHC) in the absence of a germline mutation in these genes that cannot be explained by BRAF mutation or MLH1 hypermethylation. The application of the universal strategy for the diagnosis of Lynch syndrome (LS) in all CRCs is leading to an increase in the incidence of cases of LLS. It has been described that risk of cancer in relatives of LLS patients is in between of that found in Lynch syndrome families and sporadic cases. That makes LLS patients and their families a challenging group for which the origin of CRC is unknown, being a mixture between unidentified hereditary CRC and sporadic cases. The potential causes of LLS are discussed in this review, as well as methods for identification of truly hereditary cases.Lynch syndrome is an autosomal dominant disorder caused by germline mutations in DNA mismatch repair (MMR) system genes, such as MLH1, MSH2, MSH6, or PMS2. It is the most common hereditary colorectal cancer syndrome. Screening is regularly performed by using microsatellite instability (MSI) or immunohistochemistry for the MMR proteins in tumor samples. However, in a proportion of cases, MSI is found or MMR immunohistochemistry is impaired in the absence of a germline mutation in MMR genes, BRAF mutation, or MLH1 hypermethylation. These cases are defined as Lynch-like syndrome. Patients with Lynch-like syndrome represent a mixture of truly hereditary and sporadic cases, with a risk of colorectal cancer in first-degree relatives that is between the risk of Lynch syndrome in families and relatives of sporadic colon cancer cases. Although multiple approaches have been suggested to distinguish between hereditary and sporadic cases, a homogeneous testing protocol and consensus on the adequate classification of these patients is still lacking. For this reason, management of Lynch-like syndrome and prevention of cancer in these families is clinically challenging. This review explains the concept of Lynch-like syndrome, potential mechanisms for its development, and methods for adequately distinguishing between sporadic and hereditary cases of this entity.

Highlights

  • Lynch-like syndrome (LLS) is defined as colorectal cancer cases with microsatellite instability (MSI) and loss of expression of MLH1, MSH2, MSH6, or PMS2 by immunohistochemistry (IHC) in the absence of a germline mutation in these genes that cannot be explained by BRAF mutation or MLH1 hypermethylation [1]

  • These results are supported by Win et al, who showed that the risk of a first-degree relative of an Lynch syndrome (LS) patient developing colorectal cancer (CRC) (hazard ratio (HR) = 5.37) is higher than in LLS (HR = 2.06) and mismatch repair (MMR)-D non-LS groups (HR = 1.04) (50)

  • Vargas-Parra et al, obtained the same results; they found a double somatic hit in MSH2 and MSH6 in five tumors from four LLS patients (80). All of these results agree with those obtained by Xicola et al, who showed a somatic mutation in one MMR allele and loss of heterozygosity (LOH) in the other allele in 4/9 LLS cases (3/4 in MLH1 and 1/4 in MSH2) [81]

Read more

Summary

Introduction

Lynch-like syndrome (LLS) is defined as colorectal cancer cases with microsatellite instability (MSI) and loss of expression of MLH1, MSH2, MSH6, or PMS2 by immunohistochemistry (IHC) in the absence of a germline mutation in these genes that cannot be explained by BRAF mutation or MLH1 hypermethylation [1]. Managing these cases is challenging because the subsequent carcinogenic process is yet to be unveiled. The characteristics of LLS cases, the potential causes, and recommendations on managing these cases are discussed

Carcinogenic Pathways in Colorectal Cancer
Lynch Syndrome
Lynch-like Syndrome
Demographics
Family History
Pathology and IHC
Cancer Risk
Potential Causes of Lynch-like Syndrome
Germline Mutations in Other Genes Affecting the MMR System
Hereditary Cases
Somatic Alteration in Other Cancer Genes or Epigenetic Structures
Somatic Biallelic Alteration in MMR
Future Research
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call